United States Federal Circuit
Prometheus Laboratories, Inc. v. Roxane Laboratories, Inc., 14-1634
In an infringement action involving patents related to the treatment of irritable bowel syndrome (IBS), the district court's judgment, finding the claims would have been obvious over the prior art or, in the alternative, invalid of grounds of obviousness-type double patenting, is affirmed where the claims of the '770 patent are invalid as obvious over the '800 patent and other prior art.
Appellate Information
- Decided 11/10/2015
- Published 11/10/2015
Judges
- DYK
Court
- United States Federal Circuit